ArticleDrug and alcohol dependence2022
Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States.
Article in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Assessing coronavirus disease 2019 pandemic impacts on the health of people who inject drugs using a novel data sharing model.AIDS (London, England) · 2025Pooled it
- Syringe Services Participants' Preferences for Wound Care, HIV/Hepatitis C Virus Screening, and Opioid Use Disorder Treatment: A Discrete Choice Experiment.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026Article
- Linkage to Substance Use Disorder Treatment Through Syringe Services Programs and the Criminal Legal System: A Cross-Sectional Study.American journal of preventive medicine · 2026Article
- Comparing Prescription Opioid, Benzodiazepine, and Stimulant Misuse Rates Among Patients With and Without Telehealth Service Use.The American journal of psychiatry · 2025Article
- Limited acceptance of buprenorphine in recovery residences in South Florida: A secret shopper survey.Journal of substance use and addiction treatment · 2025Article
- Racialized environments and syringe services program implementation: County-level factors.Drug and alcohol dependence · 2024Article
- Posttraumatic stress disorder in people who use drugs: syringe services program utilization, treatment need, and preferences for onsite mental health care.Harm reduction journal · 2024Article
- Comparing harm reduction and overdose response services between community-based and public health department syringe service programmes using a national cross-sectional survey.Lancet regional health. Americas · 2024Article
- Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.Addiction science & clinical practice · 2024Article
- Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.Annals of medicine · 2023Article
- Availability of telehealth-based services at syringe services programs under the COVID-19 Public Health Emergency.Harm reduction journal · 2023Article
- Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.Addiction science & clinical practice · 2023Article
- How do contextual factors influence naloxone distribution from syringe service programs in the USA: a cross-sectional study.Harm reduction journal · 2023Article
- Envisioning Minimally Disruptive Opioid Use Disorder Care.Journal of general internal medicine · 2023Article
- Commentary on Adams et al.: using administrative big data for the public good.Addiction (Abingdon, England) · 2022Article
- Syringe Service Program-Based Telemedicine Linkage to Opioid Use Disorder Treatment: Results From a Pragmatic Randomized Trial of the STAMINA Intervention.Substance use : research and treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
introductionAmong people with an opioid use disorder in the United States, only 10% receive buprenorphine treatment. The Ryan Haight Act is a federal law that has regulated buprenorphine delivery, requiring an in-person examination between a patient and provider before initiating treatment. At the beginning of the COVID-19 pandemic, federal agencies waived in-person examination requirements for buprenorphine treatment initiation. We examined whether Ryan Haight Act waiver improved implementation of telehealth buprenorphine within syringe service programs (SSPs) - organizations that serve people with historically low access to treatment.
methodsWe surveyed all known SSPs operating in the US in 2021 (N = 421) of which 77% responded (n = 325). We calculated the prevalence and accompanying 95% confidence intervals (CI) for implementation of telehealth buprenorphine inductions at SSPs in 2020. Multivariable logistic regression was used to assess differences in implementing telehealth buprenorphine inductions by organizational characteristics.
resultsIn 2020, the prevalence of implementing buprenorphine inductions via telehealth was 24% (95% CI:19-30%). Non-governmental SSPs had a higher odds of telehealth buprenorphine inductions (adjusted odds ratio (aOR)= 2.92; 95% CI:1.22-7.00; p = 0.016), compared to governmental SSPs. Furthermore, the larger the organization's annual budget, the higher the odds of telehealth buprenorphine implementation (aOR=2.00 per quartile (95% CI:1.33-2.99; p = 0.001). SSPs located in states with higher opioid overdose mortality rates did not have significantly higher likelihood of telehealth buprenorphine implementation.
conclusionA substantial number of SSPs implemented telehealth buprenorphine after waiver of the Ryan Haight Act. Permanent adoption of this waiver will be critical and providing financial resources to SSPs is vital to support implementation of new innovations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.